Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report issued on Saturday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Trading Down 6.9 %

Shares of NASDAQ EGRX opened at $0.88 on Friday. Eagle Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $6.37. The company’s 50-day moving average is $1.09 and its 200 day moving average is $1.21.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. RBF Capital LLC increased its holdings in shares of Eagle Pharmaceuticals by 11.7% during the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after acquiring an additional 14,991 shares in the last quarter. DGS Capital Management LLC increased its stake in Eagle Pharmaceuticals by 44.9% during the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after purchasing an additional 22,239 shares in the last quarter. Jane Street Group LLC purchased a new position in Eagle Pharmaceuticals in the third quarter worth about $96,000. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Eagle Pharmaceuticals during the third quarter valued at approximately $453,000. Institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.